Education
About Us
Working with TipRanks
Follow Us
BetterLife Pharma (BETRF)
OTHER OTC:BETRF
BETRF Stock Chart & Stats
$0.04
$0.02(32.60%)
At close: 4:00 PM EST
$0.04
$0.02(32.60%)
Day’s Range― - ―
52-Week Range$0.03 - $0.09
Previous CloseN/A
Volume32.97K
Average Volume (3M)43.71K
Market Cap
$6.10M
Enterprise Value$9.01M
Total Cash (Recent Filing)$7.96K
Total Debt (Recent Filing)$659.63K
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding151,896,680
10 Day Avg. Volume49,808
30 Day Avg. Volume43,712
Financial Highlights & Ratios
PEG Ratio-0.60
Price to Book (P/B)-1.51
Price to Sales (P/S)0.00
P/FCF Ratio-7.96
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash BurnTTM cash burn falling sharply indicates management has materially reduced operating outflows versus prior years. This durable improvement lengthens runway, lowers near-term financing pressure and dilution risk, and provides more time to advance R&D programs before seeking fresh capital.
Strategic Greater China PartnershipSecuring advisors and a partnership to pursue Greater China represents a structural commercial strategy shift, expanding addressable markets and potential licensing or co-development routes. That durable market-access focus can materially enhance long-term commercialization options if clinical progress continues.
Focused Therapeutic NicheConcentrating on mental health and neurological disorders aligns the company with persistent unmet clinical needs and sizable, stable demand. A focused pipeline improves ability to build expertise, target funding and partnerships, and positions the company in areas with attractive long-term regulatory and commercial tailwinds.
Bears Say
No Revenue And Ongoing LossesAbsence of revenues means the business has no internal cash generation to fund development; persistent net losses force reliance on external financing. Over the medium term this limits visibility on commercial viability and increases execution risk tied to successful clinical and regulatory outcomes.
Negative Shareholders' EquityMaterial negative equity reflects accumulated losses and a weak capital base, constraining borrowing capacity and reducing financial flexibility. This structural weakness magnifies dilution risk from future raises and lowers resilience to adverse trial or regulatory setbacks over the next several months.
Very Small Asset BaseA tiny asset base provides minimal buffer to absorb development setbacks or fund operations without accessing markets. This forces dependence on external capital and partners for clinical advancement, increasing execution risk and potential dilution over the medium term if milestones or licensing options don't materialize.
BetterLife Pharma News
BETRF FAQ
What was BetterLife Pharma’s price range in the past 12 months?
BetterLife Pharma lowest stock price was $0.03 and its highest was $0.09 in the past 12 months.
What is BetterLife Pharma’s market cap?
BetterLife Pharma’s market cap is $6.10M.
When is BetterLife Pharma’s upcoming earnings report date?
BetterLife Pharma’s upcoming earnings report date is Jun 02, 2026 which is in 101 days.
How were BetterLife Pharma’s earnings last quarter?
BetterLife Pharma released its earnings results on Dec 19, 2025. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is BetterLife Pharma overvalued?
According to Wall Street analysts BetterLife Pharma’s price is currently Overvalued.
Does BetterLife Pharma pay dividends?
BetterLife Pharma does not currently pay dividends.
What is BetterLife Pharma’s EPS estimate?
BetterLife Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BetterLife Pharma have?
BetterLife Pharma has 151,896,680 shares outstanding.
What happened to BetterLife Pharma’s price movement after its last earnings report?
BetterLife Pharma reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of BetterLife Pharma?
Currently, no hedge funds are holding shares in BETRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BetterLife Pharma
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
PharmaTher Holdings Ltd
―
Marvel Biosciences Corp
―
Doseology Sciences
―
PharmAla Biotech Holdings, Inc.
―
Ownership Overview
33.08% Insiders
<0.01% Other Institutional Investors
66.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---